[{"orgOrder":0,"company":"Radius Health","sponsor":"Gurnet Point Capital","pharmaFlowCategory":"D","therapeuticArea":"Musculoskeletal","country":"U.S.A","productType":"Peptide","year":"2022","type":"Acquisition","leadProduct":"Abaloparatide Acetate","moa":"PTH1 receptor","graph1":"Musculoskeletal","graph2":"Approved FDF","graph3":"Radius Health","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Musculoskeletal","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Radius Health \/ Gurnet Point Capital","highestDevelopmentStatusID":"15","companyTruncated":"Radius Health \/ Gurnet Point Capital"},{"orgOrder":0,"company":"Radius Health","sponsor":"Gurnet Point Capital","pharmaFlowCategory":"D","therapeuticArea":"Musculoskeletal","country":"U.S.A","productType":"Peptide","year":"2022","type":"Acquisition","leadProduct":"Abaloparatide Acetate","moa":"PTH1 receptor","graph1":"Musculoskeletal","graph2":"Approved FDF","graph3":"Radius Health","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Musculoskeletal","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Radius Health \/ Gurnet Point Capital","highestDevelopmentStatusID":"15","companyTruncated":"Radius Health \/ Gurnet Point Capital"},{"orgOrder":0,"company":"Radius Health","sponsor":"Gurnet Point Capital","pharmaFlowCategory":"D","therapeuticArea":"Musculoskeletal","country":"U.S.A","productType":"Peptide","year":"2022","type":"Acquisition","leadProduct":"Abaloparatide Acetate","moa":"PTH1 receptor","graph1":"Musculoskeletal","graph2":"Approved FDF","graph3":"Radius Health","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Musculoskeletal","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Radius Health \/ Gurnet Point Capital","highestDevelopmentStatusID":"15","companyTruncated":"Radius Health \/ Gurnet Point Capital"},{"orgOrder":0,"company":"Radius Health","sponsor":"Theramex","pharmaFlowCategory":"D","therapeuticArea":"Musculoskeletal","country":"U.S.A","productType":"Peptide","year":"2023","type":"Licensing Agreement","leadProduct":"Abaloparatide Acetate","moa":"PTH1 receptor","graph1":"Musculoskeletal","graph2":"Approved FDF","graph3":"Radius Health","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Musculoskeletal","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Radius Health \/ Theramex","highestDevelopmentStatusID":"15","companyTruncated":"Radius Health \/ Theramex"},{"orgOrder":0,"company":"Radius Health","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Musculoskeletal","country":"U.S.A","productType":"Peptide","year":"2021","type":"Inapplicable","leadProduct":"Abaloparatide Acetate","moa":"PTH1 receptor","graph1":"Musculoskeletal","graph2":"Approved FDF","graph3":"Radius Health","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Musculoskeletal","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Radius Health \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Radius Health \/ Inapplicable"},{"orgOrder":0,"company":"Radius Health","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Musculoskeletal","country":"U.S.A","productType":"Peptide","year":"2022","type":"Inapplicable","leadProduct":"Abaloparatide Acetate","moa":"PTH1 receptor","graph1":"Musculoskeletal","graph2":"Approved FDF","graph3":"Radius Health","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Musculoskeletal","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Radius Health \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Radius Health \/ Inapplicable"},{"orgOrder":0,"company":"Radius Health","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Musculoskeletal","country":"U.S.A","productType":"Peptide","year":"2020","type":"Inapplicable","leadProduct":"Abaloparatide Acetate","moa":"PTH1 receptor","graph1":"Musculoskeletal","graph2":"Approved FDF","graph3":"Radius Health","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Musculoskeletal","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Radius Health \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Radius Health \/ Inapplicable"},{"orgOrder":0,"company":"Radius Health","sponsor":"Menarini","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Elacestrant","moa":"Selective estrogen receptor","graph1":"Oncology","graph2":"Phase III","graph3":"Radius Health","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Radius Health \/ Menarini","highestDevelopmentStatusID":"10","companyTruncated":"Radius Health \/ Menarini"},{"orgOrder":0,"company":"Radius Health","sponsor":"Menarini","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Elacestrant","moa":"Selective estrogen receptor","graph1":"Oncology","graph2":"Phase III","graph3":"Radius Health","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Radius Health \/ Menarini","highestDevelopmentStatusID":"10","companyTruncated":"Radius Health \/ Menarini"},{"orgOrder":0,"company":"Radius Health","sponsor":"Ellipses Pharma","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Divestment","leadProduct":"Vosilasarm","moa":"Selective androgen receptor","graph1":"Oncology","graph2":"Phase I","graph3":"Radius Health","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Radius Health \/ Ellipses Pharma","highestDevelopmentStatusID":"6","companyTruncated":"Radius Health \/ Ellipses Pharma"},{"orgOrder":0,"company":"Radius Health","sponsor":"DRI Healthcare Trust","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Agreement","leadProduct":"Elacestrant","moa":"Selective estrogen receptor","graph1":"Oncology","graph2":"Approved FDF","graph3":"Radius Health","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet, Film Coated","sponsorNew":"Radius Health \/ DRI Healthcare Trust","highestDevelopmentStatusID":"15","companyTruncated":"Radius Health \/ DRI Healthcare Trust"},{"orgOrder":0,"company":"Radius Health","sponsor":"Theramex","pharmaFlowCategory":"D","therapeuticArea":"Musculoskeletal","country":"U.S.A","productType":"Peptide","year":"2024","type":"Licensing Agreement","leadProduct":"Abaloparatide Acetate","moa":"PTH1 receptor","graph1":"Musculoskeletal","graph2":"Approved FDF","graph3":"Radius Health","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Musculoskeletal","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Radius Health \/ Theramex","highestDevelopmentStatusID":"15","companyTruncated":"Radius Health \/ Theramex"},{"orgOrder":0,"company":"Radius Health","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Controlled Substance","year":"2021","type":"Inapplicable","leadProduct":"Cannabidiol","moa":"CB1\/2 receptor","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Radius Health","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Solution","sponsorNew":"Radius Health \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Radius Health \/ Inapplicable"},{"orgOrder":0,"company":"Radius Health","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Controlled Substance","year":"2022","type":"Inapplicable","leadProduct":"Cannabidiol","moa":"CB1\/2 receptor","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Radius Health","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Solution","sponsorNew":"Radius Health \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Radius Health \/ Inapplicable"},{"orgOrder":0,"company":"Radius Health","sponsor":"Menarini","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Licensing Agreement","leadProduct":"Elacestrant","moa":"Selective estrogen receptor","graph1":"Oncology","graph2":"Phase III","graph3":"Radius Health","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Radius Health \/ Menarini","highestDevelopmentStatusID":"10","companyTruncated":"Radius Health \/ Menarini"}]

Find Clinical Drug Pipeline Developments & Deals by Radius Health

Menu
Xls
Filters Filter
×
FILTER:
filter
Company Name
    filter

    Year

      filter

      DEALS // DEV.

        filter

        Country

          filter
          Sponsor
            filter

            Therapeutic Area

              filter

              Study Phase

                filter

                Deal Type

                  filter

                  Product Type

                    filter

                    Dosage Form

                      filter

                      Lead Product

                        filter

                        Target

                          Loading...

                          Therapeutic Area by Lead Product

                          Study Phase by Lead Product

                          Company by Lead Product

                          Top Deals by Deal Size (USD bn)

                          01

                          Cophex
                          Not Confirmed
                          Cophex
                          Not Confirmed

                          Details : Under the licensing agreement, Radius granted Theramex the exclusive commercialization rights to Eladynos (abaloparatide), indicated for the treatment of osteoporosis in postmenopausal

                          Product Name : Eladynos

                          Product Type : Peptide

                          Upfront Cash : Undisclosed

                          December 09, 2024

                          Lead Product(s) : Abaloparatide Acetate

                          Therapeutic Area : Musculoskeletal

                          Highest Development Status : Approved FDF

                          Sponsor : Theramex

                          Deal Size : Undisclosed

                          Deal Type : Licensing Agreement

                          blank

                          02

                          Cophex
                          Not Confirmed
                          Cophex
                          Not Confirmed

                          Details : Under the agreement, DRI Healthcare gains a portion of Radius’s royalty and commercial milestone stream in Orserdu (elacestrant), a selective estrogen receptor degrader and the first and only treatment approved for ER+/HER2-, ESR1- mutated advanced or ...

                          Product Name : RAD1901

                          Product Type : Other Small Molecule

                          Upfront Cash : $130.0 million

                          August 14, 2023

                          Lead Product(s) : Elacestrant

                          Therapeutic Area : Oncology

                          Highest Development Status : Approved FDF

                          Sponsor : DRI Healthcare Trust

                          Deal Size : $140.0 million

                          Deal Type : Agreement

                          blank

                          03

                          Cophex
                          Not Confirmed
                          Cophex
                          Not Confirmed

                          Details : Theramex will commercialise and distribute Eladynos (abaloparatide), a novel bone forming agent indicated for the treatment of osteoporosis in postmenopausal women at increased risk of fractures on an exclusive basis in the European Economic Area, UK , A...

                          Product Name : Tymlos

                          Product Type : Peptide

                          Upfront Cash : Undisclosed

                          March 20, 2023

                          Lead Product(s) : Abaloparatide Acetate

                          Therapeutic Area : Musculoskeletal

                          Highest Development Status : Approved FDF

                          Sponsor : Theramex

                          Deal Size : Undisclosed

                          Deal Type : Licensing Agreement

                          blank

                          04

                          Cophex
                          Not Confirmed
                          Cophex
                          Not Confirmed

                          Details : Radius’ lead product, TYMLOS® (abaloparatide) was launched in the U.S. in 2017 for the treatment of postmenopausal women with osteoporosis at high risk for fracture.

                          Product Name : Tymlos

                          Product Type : Peptide

                          Upfront Cash : Undisclosed

                          August 15, 2022

                          Lead Product(s) : Abaloparatide Acetate

                          Therapeutic Area : Musculoskeletal

                          Highest Development Status : Approved FDF

                          Sponsor : Gurnet Point Capital

                          Deal Size : Undisclosed

                          Deal Type : Acquisition

                          blank

                          05

                          Cophex
                          Not Confirmed
                          Cophex
                          Not Confirmed

                          Details : The acquisition of Radius by Gurnet Point and Patient Square provides our shareholders with attractive, immediate value at a compelling premium, in addition to the potential future upside of TYMLOS (abaloparatide) through the CVR.

                          Product Name : Tymlos

                          Product Type : Peptide

                          Upfront Cash : $547.0 million

                          August 15, 2022

                          Lead Product(s) : Abaloparatide Acetate

                          Therapeutic Area : Musculoskeletal

                          Highest Development Status : Approved FDF

                          Sponsor : Gurnet Point Capital

                          Deal Size : $890.0 million

                          Deal Type : Acquisition

                          blank

                          06

                          Cophex
                          Not Confirmed
                          Cophex
                          Not Confirmed

                          Details : Investigational drug RAD011 is a pharmaceutical-grade synthetic cannabidiol oral solution, manufactured utilizing traditional pharmaceutical manufacturing processes.

                          Product Name : RAD011

                          Product Type : Controlled Substance

                          Upfront Cash : Inapplicable

                          July 07, 2022

                          Lead Product(s) : Cannabidiol

                          Therapeutic Area : Genetic Disease

                          Highest Development Status : Phase III

                          Sponsor : Inapplicable

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          07

                          Cophex
                          Not Confirmed
                          Cophex
                          Not Confirmed

                          Details : The acquisition of Radius by Gurnet Point and Patient Square provides our shareholders with attractive, immediate value at a compelling premium, in addition to the potential future upside of TYMLOS (abaloparatide) through the CVR.

                          Product Name : Tymlos

                          Product Type : Peptide

                          Upfront Cash : $547.0 million

                          June 23, 2022

                          Lead Product(s) : Abaloparatide Acetate

                          Therapeutic Area : Musculoskeletal

                          Highest Development Status : Approved FDF

                          Sponsor : Gurnet Point Capital

                          Deal Size : $890.0 million

                          Deal Type : Acquisition

                          blank

                          08

                          Cophex
                          Not Confirmed
                          Cophex
                          Not Confirmed

                          Details : RAD1901 (elacestrant) is the first and currently only investigational oral SERD to show positive topline results in a pivotal trial for the treatment of ER+/HER2- advanced or metastatic breast cancer in postmenopausal women, and men.

                          Product Name : RAD1901

                          Product Type : Other Small Molecule

                          Upfront Cash : Inapplicable

                          June 22, 2022

                          Lead Product(s) : Elacestrant

                          Therapeutic Area : Oncology

                          Highest Development Status : Phase III

                          Sponsor : Menarini

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          09

                          Cophex
                          Not Confirmed
                          Cophex
                          Not Confirmed

                          Details : The data for spine BMD vs. baseline showed abalo-TDS had a 7.1% increase vs. TYMLOS (abaloparatide) +10.9%, both considered clinically meaningful. Despite missing the non-inferiority margin, the transdermal system demonstrated a bone building benefit to ...

                          Product Name : Tymlos

                          Product Type : Peptide

                          Upfront Cash : Inapplicable

                          January 06, 2022

                          Lead Product(s) : Abaloparatide Acetate

                          Therapeutic Area : Musculoskeletal

                          Highest Development Status : Phase III

                          Sponsor : Inapplicable

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          10

                          Cophex
                          Not Confirmed
                          Cophex
                          Not Confirmed

                          Details : Company announced phase 3 topline results from the wearABLe study did not meet its primary endpoint evaluating the NI of BA058 (abaloparatide) in postmenopausal women with osteoporosis.

                          Product Name : Tymlos

                          Product Type : Peptide

                          Upfront Cash : Inapplicable

                          August 12, 2021

                          Lead Product(s) : Abaloparatide Acetate

                          Therapeutic Area : Musculoskeletal

                          Highest Development Status : Phase III

                          Sponsor : Inapplicable

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank